Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846977 | 0.89 | AR (0.50) | ARSLC22A12FFAR1FFAR4PGR | |
| SCHEMBL23753793 | 0.89 | AR (0.50) | ARSLC22A12FFAR1FFAR4PGR | |
| SCHEMBL18189524 | 0.80 | IDH1 (0.50) | ARSLC22A12KCNJ1KCNH2IDH1 | |
| SCHEMBL20930791 | 0.80 | KCNJ1 (0.39) | ARSLC22A12KCNJ1KCNH2IDH1 | |
| SCHEMBL7660043 | 0.80 | KCNJ1 (0.39) | ARSLC22A12KCNJ1KCNH2IDH1 | |
| SCHEMBL8120210 | 0.80 | KCNJ1 (0.39) | ARSLC22A12KCNJ1KCNH2IDH1 | |
| SCHEMBL3020737 | 0.80 | SLC22A12 (0.41) | ARSLC22A12KCNJ1KCNH2IDH1 | |
| SCHEMBL21230254 | 0.80 | KCNJ1 (0.39) | ARSLC22A12KCNJ1KCNH2IDH1 | |
| SCHEMBL3020739 | 0.80 | AR (0.46) | ARSLC22A12KCNJ1KCNH2IDH1 | |
| SCHEMBL323502 | 0.80 | KDM4E (0.51) | ARSLC22A12KCNJ1KCNH2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | AR 338/4885SLC22A12 2879/4885FFAR1 4246/4885 |
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | AR 3803/4885SLC22A12 4252/4885FFAR1 3984/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | AR 3803/4885SLC22A12 4252/4885FFAR1 3984/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | AR 3714/4885SLC22A12 4254/4885FFAR1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.